Characteristics of patients at baseline
| Characteristic | rhTNK-tPA | rt-PA | ||
| 0.1 mg/kg (N=60) | 0.25 mg/kg (N=57) | 0.32 mg/kg (N=60) | 0.9 mg/kg (N=59) | |
| Age (years) | ||||
| Mean (SD) | 62.4 (11.1) | 64.3 (12.8) | 64.8 (12.1) | 66.5 (12.6) |
| Age group (n) | ||||
| <60 | 28 (46.7) | 21 (36.8) | 15 (25.0) | 17 (28.8) |
| 60–80 | 31 (51.7) | 28 (49.1) | 40 (66.7) | 36 (61.0) |
| >80 | 1 (1.7) | 8 (14.0) | 5 (8.3) | 6 (10.2) |
| Sex (n) | ||||
| Women | 12 (20.0) | 15 (26.3) | 18 (30.0) | 21 (35.6) |
| BMI (kg/m2) | ||||
| Mean (SD) | 24.52 (3.3) | 25.00 (3.8) | 24.64 (4.4) | 23.77 (3.4) |
| Hypertension (n, %) | 43 (71.7) | 37 (64.9) | 35 (58.3) | 42 (71.2) |
| Diabetes mellitus (n, %) | 14 (23.3) | 9 (15.8) | 15 (25.0) | 11 (18.6) |
| Hyperlipidaemia (n, %) | 17 (28.3) | 13 (22.8) | 10 (16.7) | 11 (18.6) |
| Atrial fibrillation (n, %) | 8 (13.3) | 4 (7.0) | 14 (23.3) | 6 (10.2) |
| Current smoking (n, %) | 25 (41.7) | 25 (43.9) | 21 (35.0) | 24 (40.7) |
| Medical history (n, %) | ||||
| Antiplatelet | 11 (18.3) | 6 (10.5) | 13 (21.7) | 13 (22.0) |
| Anticoagulant | 2 (3.3) | 0 (0.0) | 0 (0.0) | 2 (3.4) |
| NIHSS score | ||||
| Median (IQR) | 7.0 (5.0–10.0) | 8.0 (5.0–12.0) | 7.5 (6.0–12.0) | 8.0 (5.0–12.0) |
| Premorbid mRS score (n, %) | ||||
| 0 | 55 (91.7) | 54 (94.7) | 47 (78.3) | 50 (84.8) |
| 1 | 5 (8.3) | 3 (5.3) | 11 (18.3) | 5 (8.5) |
| 2 | 0 (0.0) | 0 (0.0) | 2 (3.3) | 4 (6.8) |
| Onset-to-needle time (min) | ||||
| Median (IQR) | 154 (56–195) | 149 (80–179) | 147 (69–220) | 153 (18–187) |
| Door-to-needle time (min) | ||||
| Median (IQR) | 71 (28–149) | 60 (5–180) | 69 (10–134) | 71 (10–146) |
BMI, body mass index; mRS, modified Rankin Scale; rhTNK-tPA, recombinant human tenecteplase tissue-type plasminogen activator.